Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors

In recent years, the cannabinoid type 2 receptor (CB2R) has become a major target for treating many disease conditions. The old therapeutic paradigm of “one disease-one target-one drug” is being transformed to “complex disease-many targets-one drug.” Multitargeting, therefore, attracts much attentio...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Shayma El-Atawneh, Amiram Goldblum
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Subjects:	cannabinoid receptors 2 (CB2R) multitargeting ISE virtual screening inflammation neuroprotective
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.812745/full

Similar Items

An enquiry to the role of CB1 receptors in neurodegeneration
by: Ignacio Fernández-Moncada, et al.
Published: (2023-08-01)

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor
by: Monica Patel, et al.
Published: (2023-12-01)

Cannabinoid CB1 Receptor Expression and Localization in the Dorsal Horn of Male and Female Rat and Human Spinal Cord
by: Jessica Parnell, et al.
Published: (2023-07-01)

Cannabinoid CB2 receptors and spinal microglia are implicated in tingenone-mediated antinociception in mice
by: Clarice C.V. Moura, et al.
Published: (2021-01-01)

Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
by: M. Galán-Ganga, et al.
Published: (2021-05-01)

Voltage dependence of the cannabinoid CB1 receptor
by: Esty Goldberger, et al.
Published: (2022-10-01)

Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling
by: Gemma Navarro, et al.
Published: (2024-10-01)

Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells
by: Francesca Gado, et al.
Published: (2022-05-01)

Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential
by: Barbara Vuic, et al.
Published: (2022-11-01)

Editorial: Therapeutic potential of the cannabinoid CB2 receptor
by: Reem Smoum, et al.
Published: (2022-10-01)

CB1 Cannabinoid Receptor Signaling and Biased Signaling
by: Luciana M. Leo, et al.
Published: (2021-09-01)

Fenchone Derivatives as a Novel Class of CB2 Selective Ligands: Design, Synthesis, X-ray Structure and Therapeutic Potential
by: Reem Smoum, et al.
Published: (2022-02-01)

The Impact of CB1 Receptor on Nuclear Receptors in Skeletal Muscle Cells
by: Mansour Haddad
Published: (2021-10-01)

3D-QSAR/CoMFA-Based Structure-Affinity/Selectivity Relationships of Aminoalkylindoles in the Cannabinoid CB1 and CB2 Receptors
by: Jaime Mella-Raipán, et al.
Published: (2014-03-01)

CB1 receptor and psychosis: friend, foe, or both
by: Jagadeesh S. Rao, et al.
Published: (2025-07-01)

Cannabinoid Receptor 2 (CB2) Inverse Agonist SMM-189 Induces Expression of Endogenous CB2 and Protein Kinase A That Differentially Modulates the Immune Response and Suppresses Experimental Colitis
by: Sonia Kiran, et al.
Published: (2022-04-01)

CB2 Receptors and Neuron–Glia Interactions Modulate Neurotoxicity Generated by MAGL Inhibition
by: Estefania Rojo-Bustamante, et al.
Published: (2020-08-01)

Involvement of CB1R and CB2R Ligands in Sleep Disorders and Addictive Behaviors in the Last 25 Years
by: Marcel Pérez-Morales, et al.
Published: (2025-02-01)

Characterization of Subtype Selective Cannabinoid CB<sub>2</sub> Receptor Agonists as Potential Anti-Inflammatory Agents
by: Yaliang Tang, et al.
Published: (2021-04-01)

Requiem for Rimonabant: Therapeutic Potential for Cannabinoid CB<sub>1</sub> Receptor Antagonists after the Fall
by: Taryn Bosquez-Berger, et al.
Published: (2023-08-01)

Cannabidiol interacts with the FXR/Nrf2 pathway and changes the CB1/CB2 receptors ratio in gentamicin-induced kidney injury in rats
by: Vahideh Hokmabady, et al.
Published: (2023-03-01)

Pharmacologic antagonism of CB1 receptors improves electrophysiological alterations in Purkinje cells exposed to 3-AP
by: Hoda Ranjbar, et al.
Published: (2023-03-01)

Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders
by: Hiroki Ishiguro, et al.
Published: (2018-07-01)

A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay
by: Leire Borrega-Roman, et al.
Published: (2025-04-01)

Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
by: Michelle Roche, et al.
Published: (2010-08-01)

Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia
by: Tibor Stark, et al.
Published: (2022-01-01)

Anti-inflammatory and antinociceptive effects of the selective cannabinoid CB2 receptor agonist ABK5
by: Yaliang Tang, et al.
Published: (2021-04-01)

A Critical Evaluation of Terpenoid Signaling at Cannabinoid CB1 Receptors in a Neuronal Model
by: Michaela Dvorakova, et al.
Published: (2022-09-01)

2-Arylpropionic Acid Pyrazolamides as Cannabinoid CB2 Receptor Inverse Agonists Endowed with Anti-Inflammatory Properties
by: Daniela R. de Oliveira, et al.
Published: (2022-12-01)

Sex differences in distribution of cannabinoid receptors (CB1 and CB2), S100A6 and CacyBP/SIP in human ageing hearts
by: Żaneta Piotrowska, et al.
Published: (2018-11-01)

β-Caryophyllene Mitigates Collagen Antibody Induced Arthritis (CAIA) in Mice Through a Cross-Talk between CB2 and PPAR-γ Receptors
by: Natasha Irrera, et al.
Published: (2019-07-01)

Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: A pilot study
by: Shinnyi Chou, et al.
Published: (2023-09-01)

Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility
by: Piotr Przybycień, et al.
Published: (2022-08-01)

Cannabidiol Alleviates Chronic Prostatitis and Chronic Pelvic Pain Syndrome via CB2 Receptor Activation and TRPV1 Desensitization
by: Jun Jie Piao, et al.
Published: (2025-01-01)

Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects
by: Si-Jing Hu, et al.
Published: (2022-01-01)

Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome
by: Livia Cosentino, et al.
Published: (2024-09-01)

Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB<sub>1</sub>/CB<sub>2</sub> Receptor Interaction
by: Battistina Asproni, et al.
Published: (2021-04-01)

Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist
by: Beatrice Polini, et al.
Published: (2020-12-01)

Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol—A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling
by: Jakub Jakowiecki, et al.
Published: (2021-04-01)

The Antimicrobial Properties of Cannabis and Cannabis-Derived Compounds and Relevance to CB2-Targeted Neurodegenerative Therapeutics
by: HeeJue Hong, et al.
Published: (2022-08-01)